A new publication involving insulin degludec, as part of the IDegAsp combination, was published on July 19, 2026. The paper, titled "Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study," appeared in the journal Diabetes, Obesity & Metabolism.
The publication presents post hoc analyses from the Soli-D study, examining outcomes by baseline age, disease duration, and HbA1c levels among Chinese participants with type 2 diabetes. The study compares iGlarLixi and IDegAsp, a formulation that includes insulin degludec, within these predefined subgroups.
No specific findings, efficacy outcomes, or safety data from this publication have been detailed here beyond its title and journal of record. Readers interested in the full scope of the post hoc analyses should consult the original publication listed in the sources below.
Insulin degludec remains an approved compound. For general background on insulin degludec, including its approved uses and formulations, readers can refer to the compound overview.